Sodium glycididazole enhances the efficacy of combined iodine-125 seed implantation and chemotherapy in patients with non small-cell lung cancer

Zhang,Qing; Wang,Dao‑Qing; Wu,Yu‑Fen

doi:10.3892/ol.2015.3039

Sodium glycididazole enhances the efficacy of combined iodine-125 seed implantation and chemotherapy in patients with non small-cell lung cancer

Authors:
- Qing Zhang
- Dao‑Qing Wang
- Yu‑Fen Wu
View Affiliations

Affiliations: Department of Radiology, Affiliated Hospital of Shandong Academy of Medical Sciences, Jinan, Shandong 250031, P.R. China
Published online on: March 16, 2015 https://doi.org/10.3892/ol.2015.3039
Pages: 2335-2340

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the efficacy and safety of combined therapy with iodine‑125 seed implantation and the gemcitabine plus cisplatin chemotherapeutic regimen, as well as treatment with the radiosensitizer sodium glycididazole (CMNa), in patients with non‑small cell lung cancer (NSCLC). The 40 patients with NSCLC in the experimental group (19 females; mean age, 52.3±11.5 years; age range, 34‑74 years) received the combined therapy and CMNa, and the 41 controls (13 females; mean age, 53.7±10.7 years; age range, 8‑79 years) received the combined therapy only. The response rate in the experimental group was significantly higher than in the control group (85.5 vs. 63.4%; P=0.027), with no apparent complications. Therefore, it was concluded that such therapy may be reliable and well‑tolerated for the treatment of patients with NSCLC.

View Figures

View References

1	Devesa SS, Bray F, Vizcaino AP and Parkin DM: International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 117:294–299. 2005. View Article : Google Scholar : PubMed/NCBI
2	Cardona AF, Reveiz L, Ospina EG, et al: Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database Syst Rev. CD004284:2008. View Article : Google Scholar
3	Ebara S, Katayama N, Tanimoto R, et al: Iodine-125 seed implantation (permanent brachytherapy) for clinically localized prostate cancer. Acta Med Okayama. 62:9–13. 2008.PubMed/NCBI
4	Nag S, DeHaan M, Scruggs G, Mayr N and Martin EW: Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys. 64:736–744. 2006. View Article : Google Scholar : PubMed/NCBI
5	Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
6	Shen G and Bao Y: Sodium Glycididazole Clinical Trial Cooperative Group: Double blind randomized clinical trail phase II on the sensitization by sodium glycididazole injection. Chin J Radiat Oncol. 12:254–258. 2003.(In Chinese). View Article : Google Scholar
7	Wang XP, Yun S, Zhang XL and Ding W: Primary clinical study of radiosensitizer CMNa. Chin Clin Oncol. 8:28–32. 2003.(In Chinese).
8	Zeng YC, Wu R, Xu ZG, et al: Safety and radiation-enhancing effect of sodium glycididazole in locoregionally advanced laryngeal cancers previously treated with platinum-containing chemotherapy regimens: A preliminary report. Cancer Radiother. 14:59–64. 2010. View Article : Google Scholar : PubMed/NCBI
9	Liu MZ, He LR, Lu TX, et al: Effect of hypoxic radiosensitizer sodium glycididazole on long-term result of radiotherapy for nasopharyngeal carcinoma. Chin J Oncol. 28:932–937. 2006.(In Chinese).
10	Yang J, Liu MZ, Cai L, et al: Phase II clinical trial of sodium glyci-didazole (CM-Na) combined with concurrent radiochemotherapy for advanced esophageal carcinoma. Chin J Cancer. 622–626. 2008.(In Chinese).
11	He ZY, Li FY, Tong Q, Liao ZW, Guan XX and Wang W: Concurrent chemoradiotherapy with sodium glycididazole and cisplatin for local advanced nasopharyngeal carcinoma. J First Mil Med Univ. 28:2038–2040. 2008.(In Chinese).
12	International Union Against Cancer (UICC): Lung and Pleural TumoursTNM Classification of Malignant Tumours. Sobin LH, Gospodarowicz MK and Wittekind C: 7th. Wiley-Blackwell; New York, NY: pp. 99–106. 2009
13	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
14	National Cancer Institute, . Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Accessed. June 14–2010.
15	Hu XK, Wang MY, Yang ZG, et al: The study of curing central-type lung cancer by CT guided percutaneous embedding of 125I seeds. Chin J Radiol. 38:910–915. 2004.(In Chinese).
16	Ling CC: Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys. 23:81–87. 1992. View Article : Google Scholar : PubMed/NCBI
17	Blasko JC, Mate T, Sylvester JE, Grimm PD and Cavanagh W: Brachytherapy for carcinoma of the prostate: techniques, patient selection and clinical outcomes. Semin Radiat Oncol. 12:81–94. 2002. View Article : Google Scholar : PubMed/NCBI
18	Henry AM, Al-Qaisieh B, Gould K, et al: Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of Leeds 10-year single-center brachytherapy experience. Int J Radiat Oncol Biol Phys. 76:50–56. 2010. View Article : Google Scholar : PubMed/NCBI
19	Kubota K, Nishiwaki Y, Ohashi Y, et al: The Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts). 22 (Suppl):70062004.
20	Vokes EE, Choy H, Gandara D and Mattson K: Adjuvant and neoadjuvant treatments for NSCLC. Lung Cancer. 38 (Suppl 4):29–35. 2002. View Article : Google Scholar : PubMed/NCBI
21	Chen A, Galloway M, Landreneau R, et al: Intraoperative 125I brachytherapy for high-risk stage I non-small cell lung carcinoma. Int J Radiat Oncol Biol Phys. 44:1057–1063. 1999. View Article : Google Scholar : PubMed/NCBI
22	Depierre A, Milleron B, Moro-Sibilot D, et al: French Thoracic Cooperative Group: Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol. 20:247–253. 2002. View Article : Google Scholar : PubMed/NCBI
23	Zheng X, Meng X, Zhao F, LI Y and GAO J: The in situ tumor response to radiosensitization of a novel sensitizer sodium glycididazole. J Radiat Res Radiat Process. 18:91–95. 2000.(In Chinese).
24	Zhang X, Ji HB, Chen ZH, OuYang XN and Yang RJ: Lung cancer radiosensitization by CMNa in vitro and in vivo. Chin J Radiol Med and Prot. 25:316–318. 2005.(In Chinese).
25	Lei KJ, Wang J, Jia YM and Cao YY: Chemo-sensitivity-enhancing effects of low dose glycididazolum natrium on patients with advanced non-small cell lung cancer during intervention. Chinese-German J Clin Oncol. 9:385–387. 2010.(In Chinese). View Article : Google Scholar
26	Lei KJ, Jia YM, Wang J and Du YP: Effects of CMNa combined with paclitaxel and carboplatin on elevated CA12-5 levels in post-operation advanced ovarian cancer patients. Chinese-German J Clin Oncol. 7:600–602. 2008.(In Chinese). View Article : Google Scholar
27	Brach B, Buhler C, Hayman MH, Joyner LR Jr and Liprie SF: Percutaneous computed tomography-guided fine needle brachytherapy of pulmonary malignancies. Chest. 106:268–274. 1994. View Article : Google Scholar : PubMed/NCBI
28	Martinez-Monge R, Pagola M, Vivas I and Lopez-Picazo JM: CT-guided permanent brachytherapy for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC). Lung Cancer. 61:209–213. 2008. View Article : Google Scholar : PubMed/NCBI
29	Lewis JW Jr, Ajlouni M, Kvale PA, et al: Role of brachytherapy in the management of pulmonary and mediastinal malignancies. Ann Thorac Surg. 49:728–733. 1990. View Article : Google Scholar : PubMed/NCBI
30	Fu LQ, Huang F, Guo JH, et al: Phase I clinical pharmacokinetics of glycididazolum natrium. Chin J Pharm Toxicol. 18:87–92. 2004.(In Chinese).
31	Gao HJ, Shen G, Wang HM, et al: Phase I clinical trail of sodium glycididadole (CMNa) in cancer patients. Chin J New Drugs. 13:260–263. 2004.(In Chinese).